Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Debt Ratio (2022 - 2025)

BioXcel Therapeutics has reported Debt Ratio over the past 4 years, most recently at 2.44 for Q4 2025.

  • Quarterly results put Debt Ratio at 2.44 for Q4 2025, down 8.74% from a year ago — trailing twelve months through Dec 2025 was 2.44 (down 8.74% YoY), and the annual figure for FY2025 was 2.44, down 8.74%.
  • Debt Ratio for Q4 2025 was 2.44 at BioXcel Therapeutics, roughly flat from 2.44 in the prior quarter.
  • Over the last five years, Debt Ratio for BTAI hit a ceiling of 4.21 in Q2 2025 and a floor of 0.0 in Q1 2022.
  • Median Debt Ratio over the past 4 years was 1.3 (2024), compared with a mean of 1.51.
  • Biggest five-year swings in Debt Ratio: skyrocketed 199612.67% in 2023 and later dropped 8.74% in 2025.
  • BioXcel Therapeutics' Debt Ratio stood at 0.45 in 2022, then skyrocketed by 200.59% to 1.36 in 2023, then soared by 95.89% to 2.67 in 2024, then fell by 8.74% to 2.44 in 2025.
  • The last three reported values for Debt Ratio were 2.44 (Q4 2025), 2.44 (Q3 2025), and 4.21 (Q2 2025) per Business Quant data.